Prevalence of Dio2(T92A) Polymorphism and Its Association with Thyroid Autoimmunity

Overview

Journal J Endocrinol Invest

Publisher Springer

Specialty Endocrinology

Date 2012 Sep 28

PMID 23013882

Citations 4

Authors

A Guerra

M R Sapio

M Carrano

V Di Stasi

A Volpe

A Murino

G Izzo

M Vitale

Affiliations

Soon will be listed here.

Abstract

The 3,5,3'-L-triiodothyronine (T₃) partly derives by the deiodination of the prohormone 3,5,3',5'-L-tetraiodothyronine (T₄) by the type 2 iodothyronine deiodinase (D2). The single-nucleotide polymorphism in the D2 gene at position 92 (Dio(2T92A)), generates an enzyme with a reduced T₄ to T₃ conversion velocity. Because thyroid hormones can modulate the immune response, we hypothesized a pathophysiological role for Dio(2T92A) polymorphism in autoimmunity. The objective of this study was to investigate the Dio(2T92A) polymorphism in relation to thyroid autoimmunity (TA). We compared the prevalence of Dio(2T92A) polymorphism and serum thyroid hormone levels in healthy subjects and subjects with TA. A total of 110 subjects with TA and 106 controls were genotypized for Dio(2T92A) polymorphism. Free T₃ (FT₃), free T₄ (FT₄) and TSH were measured and compared with the Dio(2T92A) polymorphism. Dio(292T/A), Dio(292A/A), and Dio(292T/T) healthy subjects were 40.9%, 46.4%, and 12.7%, respectively. These prevalences were similar to those of some European countries whilst significantly different from that of Brazil. In the two groups of healthy subjects and TA subjects, Dio(2T92A) polymorphism had a similar distribution with non-significant differences. Similarly, no significant differences were observed in the serum concentration of FT₃, FT₄, and TSH between subjects with different Dio(2T92A) polymorphism. The FT₄/FT₃, and TSH/FT₃ ratios were higher in Dio(292T/T) than in Dio(292T/A) and Dio(292A/A) subjects in both TA and healthy groups, but these differences were not significant. In conclusion, the distribution of Dio(2T92A) polymorphism may reflect geographical and ethnic differences, and it is not associated with TA.

Citing Articles

An Assessment of (rs1050450), (rs225014) and (rs7579) Gene Polymorphisms in Women with Endometrial Cancer.

Janowska M, Potocka N, Paszek S, Skrzypa M, Zulewicz K, Kluz M Genes (Basel). 2022; 13(2).

PMID: 35205233 PMC: 8871918. DOI: 10.3390/genes13020188.

Hypertension in Thyroid Disorders.

Berta E, Lengyel I, Halmi S, Zrinyi M, Erdei A, Harangi M Front Endocrinol (Lausanne). 2019; 10:482.

PMID: 31379748 PMC: 6652798. DOI: 10.3389/fendo.2019.00482.

Fas/FasL gene polymorphism in patients with Hashimoto's thyroiditis in Turkish population.

Erdogan M, Kulaksizoglu M, Ganidagli S, Berdeli A J Endocrinol Invest. 2016; 40(1):77-82.

PMID: 27572459 DOI: 10.1007/s40618-016-0534-5.

TP53 polymorphism may contribute to genetic susceptibility to develop Hashimoto's thyroiditis.

Ruggeri R, Vicchio T, Giovinazzo S, Certo R, Alibrandi A, Trimarchi F J Endocrinol Invest. 2015; 38(11):1175-82.

PMID: 25935255 DOI: 10.1007/s40618-015-0292-9.

References

Klecha A, Genaro A, Lysionek A, Caro R, Coluccia A, Cremaschi G . Experimental evidence pointing to the bidirectional interaction between the immune system and the thyroid axis. Int J Immunopharmacol. 2000; 22(7):491-500. DOI: 10.1016/s0192-0561(00)00012-6. View

Siegmund W, Spieker K, Weike A, Giessmann T, Modess C, Dabers T . Replacement therapy with levothyroxine plus triiodothyronine (bioavailable molar ratio 14 : 1) is not superior to thyroxine alone to improve well-being and cognitive performance in hypothyroidism. Clin Endocrinol (Oxf). 2004; 60(6):750-7. DOI: 10.1111/j.1365-2265.2004.02050.x. View

Mentuccia D, Proietti-Pannunzi L, Tanner K, Bacci V, Pollin T, Poehlman E . Association between a novel variant of the human type 2 deiodinase gene Thr92Ala and insulin resistance: evidence of interaction with the Trp64Arg variant of the beta-3-adrenergic receptor. Diabetes. 2002; 51(3):880-3. DOI: 10.2337/diabetes.51.3.880. View

Barreiro Arcos M, Sterle H, Paulazo M, Valli E, Klecha A, Isse B . Cooperative nongenomic and genomic actions on thyroid hormone mediated-modulation of T cell proliferation involve up-regulation of thyroid hormone receptor and inducible nitric oxide synthase expression. J Cell Physiol. 2011; 226(12):3208-18. DOI: 10.1002/jcp.22681. View

Canani L, Capp C, Dora J, Meyer E, Wagner M, Harney J . The type 2 deiodinase A/G (Thr92Ala) polymorphism is associated with decreased enzyme velocity and increased insulin resistance in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2005; 90(6):3472-8. DOI: 10.1210/jc.2004-1977. View

Saravanan P, Roberts N, Vedhara K, Greenwood R, Dayan C . Psychological well-being in patients on 'adequate' doses of l-thyroxine: results of a large, controlled community-based questionnaire study. Clin Endocrinol (Oxf). 2002; 57(5):577-85. DOI: 10.1046/j.1365-2265.2002.01654.x. View

Walsh J . Dissatisfaction with thyroxine therapy - could the patients be right?. Curr Opin Pharmacol. 2002; 2(6):717-22. DOI: 10.1016/s1471-4892(02)00209-6. View

Bunevicius R, Kazanavicius G, Zalinkevicius R, Prange Jr A . Effects of thyroxine as compared with thyroxine plus triiodothyronine in patients with hypothyroidism. N Engl J Med. 1999; 340(6):424-9. DOI: 10.1056/NEJM199902113400603. View

Marino F, Guasti L, Cosentino M, De Piazza D, Simoni C, Piantanida E . Thyroid hormone regulation of cell migration and oxidative metabolism in polymorphonuclear leukocytes: clinical evidence in thyroidectomized subjects on thyroxine replacement therapy. Life Sci. 2005; 78(10):1071-7. DOI: 10.1016/j.lfs.2005.06.016. View

10.

De Vito P, Incerpi S, Pedersen J, Luly P, Davis F, Davis P . Thyroid hormones as modulators of immune activities at the cellular level. Thyroid. 2011; 21(8):879-90. DOI: 10.1089/thy.2010.0429. View

11.

Bianco A, Kim B . Deiodinases: implications of the local control of thyroid hormone action. J Clin Invest. 2006; 116(10):2571-9. PMC: 1578599. DOI: 10.1172/JCI29812. View

12.

Baqui M, Botero D, Gereben B, Curcio C, Harney J, Salvatore D . Human type 3 iodothyronine selenodeiodinase is located in the plasma membrane and undergoes rapid internalization to endosomes. J Biol Chem. 2002; 278(2):1206-11. DOI: 10.1074/jbc.M210266200. View

13.

Heemstra K, Hoftijzer H, Van der Deure W, Peeters R, Hamdy N, Pereira A . The type 2 deiodinase Thr92Ala polymorphism is associated with increased bone turnover and decreased femoral neck bone mineral density. J Bone Miner Res. 2010; 25(6):1385-91. DOI: 10.1002/jbmr.27. View

14.

Grarup N, Andersen M, Andreasen C, Albrechtsen A, Borch-Johnsen K, Jorgensen T . Studies of the common DIO2 Thr92Ala polymorphism and metabolic phenotypes in 7342 Danish white subjects. J Clin Endocrinol Metab. 2006; 92(1):363-6. DOI: 10.1210/jc.2006-1958. View

15.

Bunevicius R, Prange A . Mental improvement after replacement therapy with thyroxine plus triiodothyronine: relationship to cause of hypothyroidism. Int J Neuropsychopharmacol. 2001; 3(2):167-174. DOI: 10.1017/S1461145700001826. View

16.

Slawik M, Klawitter B, Meiser E, Schories M, Zwermann O, Borm K . Thyroid hormone replacement for central hypothyroidism: a randomized controlled trial comparing two doses of thyroxine (T4) with a combination of T4 and triiodothyronine. J Clin Endocrinol Metab. 2007; 92(11):4115-22. DOI: 10.1210/jc.2007-0297. View

17.

Panicker V, Saravanan P, Vaidya B, Evans J, Hattersley A, Frayling T . Common variation in the DIO2 gene predicts baseline psychological well-being and response to combination thyroxine plus triiodothyronine therapy in hypothyroid patients. J Clin Endocrinol Metab. 2009; 94(5):1623-9. DOI: 10.1210/jc.2008-1301. View

18.

Bianco A, Salvatore D, Gereben B, Berry M, Larsen P . Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocr Rev. 2002; 23(1):38-89. DOI: 10.1210/edrv.23.1.0455. View

19.

Escobar-Morreale H, Botella-Carretero J, Gomez-Bueno M, Galan J, Barrios V, Sancho J . Thyroid hormone replacement therapy in primary hypothyroidism: a randomized trial comparing L-thyroxine plus liothyronine with L-thyroxine alone. Ann Intern Med. 2005; 142(6):412-24. DOI: 10.7326/0003-4819-142-6-200503150-00007. View